Oppenheimer Trims Amedisys (NASDAQ:AMED) Target Price to $175.00

Amedisys (NASDAQ:AMED – Get Rating) had its price target trimmed by Oppenheimer from $200.00 to $175.00 in a research report sent to investors on Friday, The Fly reports. Oppenheimer also issued estimates for Amedisys’ Q3 2022 earnings at $1.30 EPS and FY2022 earnings at $5.42 EPS.

Several other brokerages have also weighed in on AMED. Truist Financial reduced their price objective on Amedisys from $175.00 to $150.00 and set a buy rating for the company in a report on Thursday, July 14th. Stifel Nicolaus initiated coverage on Amedisys in a report on Tuesday, June 28th. They set a hold rating and a $128.00 price objective for the company. Bank of America downgraded Amedisys from a neutral rating to an underperform rating and dropped their target price for the stock from $145.00 to $102.00 in a research report on Tuesday, June 21st. Stephens dropped their target price on Amedisys from $155.00 to $125.00 and set an equal weight rating on the stock in a research report on Tuesday, June 21st. Finally, Barclays dropped their target price on Amedisys from $181.00 to $154.00 and set a maintains rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Hold and a consensus target price of $160.88.

Amedisys Stock Performance

AMED stock opened at $119.85 on Friday. The firm has a market cap of $3.90 billion, a PE ratio of 20.63, a P/E/G ratio of 2.48 and a beta of 0.90. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.42. The business has a 50 day moving average of $117.81 and a 200-day moving average of $135.30. Amedisys has a 12-month low of $101.61 and a 12-month high of $264.10.

Amedisys (NASDAQ:AMED – Get Rating) last announced its quarterly earnings data on Wednesday, July 27th. The health services provider reported $1.47 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.24. Amedisys had a return on equity of 19.37% and a net margin of 8.59%. The business had revenue of $557.89 million during the quarter, compared to analyst estimates of $583.12 million. During the same period in the prior year, the company earned $1.69 earnings per share. Amedisys’s revenue was down 1.1% compared to the same quarter last year. As a group, sell-side analysts expect that Amedisys will post 5.29 earnings per share for the current year.

Insider Activity at Amedisys

In related news, insider Denise M. Bohnert sold 557 shares of the stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $115.00, for a total value of $64,055.00. Following the transaction, the insider now owns 11,850 shares of the company’s stock, valued at $1,362,750. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AMED. Covestor Ltd bought a new position in shares of Amedisys during the fourth quarter valued at about $28,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Amedisys by 55.3% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 233 shares of the health services provider’s stock valued at $38,000 after buying an additional 83 shares during the last quarter. Allworth Financial LP bought a new position in shares of Amedisys during the first quarter valued at about $38,000. Confluence Wealth Services Inc. bought a new position in shares of Amedisys during the fourth quarter valued at about $42,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in shares of Amedisys during the first quarter valued at about $46,000. Institutional investors own 90.47% of the company’s stock.

About Amedisys

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

• Get a free copy of the StockNews.com research report on Amedisys (AMED)
• Use These To Find Your Stock’s Support and Resistance Levels
• Is Boeing Stock is Ready for Lift-Off ?
• Elon Musk is Out, But Should You Be In Twitter Stock?
• 3 Earnings Announcements That Could Surprise
• Twitter’s Up For Third Week In A Row: What’s Next For The Stock?

Want More Great Investing Ideas?